{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:47:03Z","timestamp":1777312023250,"version":"3.51.4"},"reference-count":44,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,16]]},"abstract":"<jats:p>Background: Treatment options for patients with critical Coronavirus Disease 2019 (COVID-19) are limited. This study aimed to describe the clinical characteristics and outcomes associated with remdesivir therapy in patients with COVID-19 who require non-invasive (NIV) ventilation or invasive mechanical ventilation (IMV).<\/jats:p>\n                  <jats:p>Methods: Data were retrospectively extracted for adults with COVID-19 confirmed using polymerase chain reaction (PCR) between August 1, 2020 and January 28, 2021 who received \u2265\u00a048 hours of remdesivir therapy while on NIV or IMV. Clinical improvement was defined as two-category improvement on an eight-point ordinal severity scale.<\/jats:p>\n                  <jats:p>Results: A total of 133 individuals were included, of which 114 (85.7%) were on NIV and 19 (14.3%) were on IMV at the time of remdesivir initiation. The majority of the patients were males (62.4%), and the median age was 56 years. All the patients received concomitant dexamethasone therapy. Remdesivir treatment was commenced after a median of 7 days from onset of symptoms and was continued for a median of 5 days.<\/jats:p>\n                  <jats:p>Clinical improvement within 28 days was achieved in 101 patients (75.9%); among which, 78.1% and 63.2% were subjected to baseline NIV and IMV, respectively. Among the 11 (8.3%) patients who died of any cause by day 28, 9 (7.9%) and 2 (10.5%) were subjected to baseline NIV and IMV, respectively. The most frequent adverse events were sinus bradycardia (21, 13.1%) and alanine transaminase increase (18, 11.3%). Almost all adverse events were classified as Grades 1\u20133.<\/jats:p>\n                  <jats:p>Conclusion: The use of remdesivir in combination with systemic corticosteroids is associated with high recovery rates and low all-cause mortality in patients with COVID-19 pneumonia who require NIV or IMV. The results need confirmation from clinical trials of appropriate design and size.<\/jats:p>","DOI":"10.5339\/qmj.2022.25","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T04:30:32Z","timestamp":1656563432000},"source":"Crossref","is-referenced-by-count":2,"title":["Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support"],"prefix":"10.5339","volume":"2022","author":[{"given":"Rim S.","family":"Alibrahim","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Z.","family":"Elmekaty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Z. I.","family":"Elmekaty","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Education, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Edbais","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rumailah Hospital, Hamad Medical Corporation, Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Daghfal","sequence":"additional","affiliation":[{"name":"Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar E-mail: aomrani@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna A.","family":"Almaslamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali S.","family":"Omrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"issue":"371:","key":"CIT0001","series-title":"BMJ","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"2020;"},{"issue":"324:","key":"CIT0002","series-title":"JAMA","first-page":"1330\u201341","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"2020;"},{"issue":"27:","key":"CIT0003","series-title":"Clin Microbiol Infect","first-page":"215\u201327","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"2021;"},{"issue":"65:","key":"CIT0004","series-title":"Antimicrob Agents Chemother","first-page":"e01814\u201320","article-title":"New perspectives on antimicrobial agents: remdesivir treatment for COVID-19","volume":"2020;"},{"issue":"383:","key":"CIT0005","series-title":"N Engl J Med","first-page":"1813\u201326","article-title":"Remdesivir for the treatment of Covid-19\u2014Final Report","volume":"2020;"},{"key":"CIT0006","article-title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19"},{"key":"CIT0007","article-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"},{"key":"CIT0008","article-title":"Australian guidelines for the clinical care of people with COVID-19. Version 40.1."},{"key":"CIT0009","article-title":"Common Terminology Criteria for Adverse Events"},{"issue":"20:","key":"CIT0010","series-title":"BMC Infect Dis","first-page":"777","article-title":"The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study","volume":"2020;"},{"issue":"11:","key":"CIT0011","series-title":"Sci Rep","first-page":"6233","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"2021;"},{"issue":"11:","key":"CIT0012","series-title":"Nat Commun","first-page":"5493","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"2020;"},{"issue":"395:","key":"CIT0013","series-title":"Lancet","first-page":"1569\u201378","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"2020;"},{"issue":"27:","key":"CIT0014","series-title":"Clin Microbiol Infect","first-page":"917.e1\u20134","article-title":"A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel","volume":"2021;"},{"issue":"323:","key":"CIT0015","series-title":"JAMA","first-page":"1574\u201381","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy","volume":"2020;"},{"issue":"395:","key":"CIT0016","series-title":"Lancet","first-page":"1763\u201370","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study","volume":"2020;"},{"issue":"73:","key":"CIT0017","series-title":"Clin Infect Dis","first-page":"2031\u20136","article-title":"Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study","volume":"2021;"},{"issue":"384:","key":"CIT0018","series-title":"N Engl J Med","first-page":"497\u2013511","article-title":"Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results","volume":"2021;"},{"issue":"83:","key":"CIT0019","series-title":"J Infect","first-page":"237\u201379","article-title":"Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)","volume":"2021;"},{"issue":"27:","key":"CIT0020","series-title":"Clin Microbiol Infect","first-page":"791.e5\u20138","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","volume":"2021;"},{"issue":"382:","key":"CIT0021","series-title":"N Engl J Med","first-page":"2327\u201336","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"2020;"},{"issue":"73:","key":"CIT0022","series-title":"Clin Infect Dis","first-page":"e4166\u201374","article-title":"Remdesivir for severe coronavirus disease (COVID-19) versus a cohort receiving standard of care","volume":"2021;"},{"issue":"371:","key":"CIT0001","series-title":"BMJ","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"2020;"},{"issue":"324:","key":"CIT0002","series-title":"JAMA","first-page":"1330\u201341","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"2020;"},{"issue":"27:","key":"CIT0003","series-title":"Clin Microbiol Infect","first-page":"215\u201327","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"2021;"},{"issue":"65:","key":"CIT0004","series-title":"Antimicrob Agents Chemother","first-page":"e01814\u201320","article-title":"New perspectives on antimicrobial agents: remdesivir treatment for COVID-19","volume":"2020;"},{"issue":"383:","key":"CIT0005","series-title":"N Engl J Med","first-page":"1813\u201326","article-title":"Remdesivir for the treatment of Covid-19\u2014Final Report","volume":"2020;"},{"key":"CIT0006","article-title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19"},{"key":"CIT0007","article-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines"},{"key":"CIT0008","article-title":"Australian guidelines for the clinical care of people with COVID-19. Version 40.1."},{"key":"CIT0009","article-title":"Common Terminology Criteria for Adverse Events"},{"issue":"20:","key":"CIT0010","series-title":"BMC Infect Dis","first-page":"777","article-title":"The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study","volume":"2020;"},{"issue":"11:","key":"CIT0011","series-title":"Sci Rep","first-page":"6233","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"2021;"},{"issue":"11:","key":"CIT0012","series-title":"Nat Commun","first-page":"5493","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"2020;"},{"issue":"395:","key":"CIT0013","series-title":"Lancet","first-page":"1569\u201378","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"2020;"},{"issue":"27:","key":"CIT0014","series-title":"Clin Microbiol Infect","first-page":"917.e1\u20134","article-title":"A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel","volume":"2021;"},{"issue":"323:","key":"CIT0015","series-title":"JAMA","first-page":"1574\u201381","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy","volume":"2020;"},{"issue":"395:","key":"CIT0016","series-title":"Lancet","first-page":"1763\u201370","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study","volume":"2020;"},{"issue":"73:","key":"CIT0017","series-title":"Clin Infect Dis","first-page":"2031\u20136","article-title":"Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study","volume":"2021;"},{"issue":"384:","key":"CIT0018","series-title":"N Engl J Med","first-page":"497\u2013511","article-title":"Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results","volume":"2021;"},{"issue":"83:","key":"CIT0019","series-title":"J Infect","first-page":"237\u201379","article-title":"Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)","volume":"2021;"},{"issue":"27:","key":"CIT0020","series-title":"Clin Microbiol Infect","first-page":"791.e5\u20138","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","volume":"2021;"},{"issue":"382:","key":"CIT0021","series-title":"N Engl J Med","first-page":"2327\u201336","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"2020;"},{"issue":"73:","key":"CIT0022","series-title":"Clin Infect Dis","first-page":"e4166\u201374","article-title":"Remdesivir for severe coronavirus disease (COVID-19) versus a cohort receiving standard of care","volume":"2021;"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/3\/article-25.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/3\/article-25.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/3\/article-25.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:10:37Z","timestamp":1777309837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/3\/article-25.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":44,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2022.25","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}